XNK Therapeu cs AB (“XNK”) today announced that Linda Brick, Head of QA, will be speaking at the 8 th CAR- TCR Summit in Boston. The annual CAR-TCR Summit is the world’s pre-eminent industry-leading comprehensive

XNK Therapeutics AB (“XNK”) today announced that Dr. David Berglund and Dr. Stephen Wooding are proposed to be appointed members of the Board of Directors. The decision will be taken at an extra general meeting on October 4, and a notice will be sent out separately.

Oct 5, 2023 · XNK Therapeutics AB today announced that Anna-Karin Maltais, Chief Scientific Officer, will be speaking at the 2[nd] Annual Innate Killer Europe Summit in London on October 18.

I denna integritetspolicy redogörs närmare för hur XNK Therapeutics AB (”Bolaget”) behandlar personuppgifter om dig i din egenskap av aktieägare eller representant för aktieägare eller innehavare eller representant för innehavare av andra finansiella instrument som kan omvandlas till, konverteras till eller ger rätt att förvärva ...

XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Gunilla Enblad, Professor of oncology at Uppsala University, and Dr. Rizwan Romee, Associate Professor of Medicine at Harvard Medical School, as scientific advisors.

Dec 11, 2020 · XNK Therapeutics AB (“XNK”) announces its collaboration agreement with Israel-based Cellect Biotechnology (“Cellect”) to develop the next generation version of XNK’s innovative technology platform.

Aktieägarna i XNK Therapeutics AB (publ), org.nr 556894–6601, kallas härmed till årsstämma tisdagen den 13 juni 2023 kl. 17.00 i bolagets lokaler, Novum, plan 8 (hiss E), Hälsovägen 7, Huddinge. Anmälan m.m.

May 7, 2018 · XNK Therapeutics AB (“XNK”) today announced it strengthened its organization by appointing Agneta Edberg to the board of directors. Agneta Edberg has over 25 years’ experience from leading positions in the life sciences industry.

XNK Therapeutics AB (“XNK”) today announced that the company’s autologous natural killer (NK) cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor in liver cancer under a research agreement with a global

Dec 1, 2021 · XNK Therapeutics AB’s CEO, Johan Liwing, will present at the ABGSC Private Companies event on December 6. The presentation starts at 09:30CET and will be livestreamed via https://www.introduce.se.